Roche provides update on astegolimab in chronic obstructive pulmonary disease
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Subscribe To Our Newsletter & Stay Updated